79 related articles for article (PubMed ID: 30237140)
41. Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.
Chen LW; Kuang F; Wei LC; Ding YX; Yung KK; Chan YS
CNS Neurol Disord Drug Targets; 2011 Jun; 10(4):449-58. PubMed ID: 21495962
[TBL] [Abstract][Full Text] [Related]
42. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
Hattori N
Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
[TBL] [Abstract][Full Text] [Related]
43. CHCHD2 and CHCHD10-related neurodegeneration: molecular pathogenesis and the path to precision therapy.
Shammas MK; Huang TH; Narendra DP
Biochem Soc Trans; 2023 Apr; 51(2):797-809. PubMed ID: 37021679
[TBL] [Abstract][Full Text] [Related]
44. New Genes Causing Hereditary Parkinson's Disease or Parkinsonism.
Puschmann A
Curr Neurol Neurosci Rep; 2017 Sep; 17(9):66. PubMed ID: 28733970
[TBL] [Abstract][Full Text] [Related]
45. Advances in the Application of Induced Pluripotent Stem Cells in Alzheimer's Disease and Parkinson's Disease.
Xu Y; Wang S; Zhu P
Curr Stem Cell Res Ther; 2023; 18(2):154-162. PubMed ID: 35473516
[TBL] [Abstract][Full Text] [Related]
46. Mitochondrial CHCHD2 and CHCHD10: Roles in Neurological Diseases and Therapeutic Implications.
Zhou W; Ma D; Tan EK
Neuroscientist; 2020 Apr; 26(2):170-184. PubMed ID: 31526091
[No Abstract] [Full Text] [Related]
47. Twin CHCH Proteins, CHCHD2, and CHCHD10: Key Molecules of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.
Imai Y; Meng H; Shiba-Fukushima K; Hattori N
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791515
[TBL] [Abstract][Full Text] [Related]
48. [The causative gene of Parkinsonism and its medical treatment strategy].
Inden M
Yakugaku Zasshi; 2014; 134(12):1253-8. PubMed ID: 25452235
[TBL] [Abstract][Full Text] [Related]
49. iPS cells in the study of PD molecular pathogenesis.
Cobb MM; Ravisankar A; Skibinski G; Finkbeiner S
Cell Tissue Res; 2018 Jul; 373(1):61-77. PubMed ID: 29234887
[TBL] [Abstract][Full Text] [Related]
50. Cellular reprogramming: a new approach to modelling Parkinson's disease.
Hartfield EM; Fernandes HJ; Vowles J; Cowley SA; Wade-Martins R
Biochem Soc Trans; 2012 Oct; 40(5):1152-7. PubMed ID: 22988881
[TBL] [Abstract][Full Text] [Related]
51. Road to future: iPSC clinical application in Parkinson's disease treatment.
Xu L; Tan YY; Wu L; Wang LL; Li H; Ding JQ; Chen SD
Curr Mol Med; 2013 Nov; 13(9):1412-8. PubMed ID: 23971738
[TBL] [Abstract][Full Text] [Related]
52. The Progress of Induced Pluripotent Stem Cells as Models of Parkinson's Disease.
Kang JF; Tang BS; Guo JF
Stem Cells Int; 2016; 2016():4126214. PubMed ID: 26880962
[TBL] [Abstract][Full Text] [Related]
53. What we can learn from iPSC-derived cellular models of Parkinson's disease.
Caiazza MC; Lang C; Wade-Martins R
Prog Brain Res; 2020; 252():3-25. PubMed ID: 32247368
[TBL] [Abstract][Full Text] [Related]
54. Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing.
Jia F; Fellner A; Kumar KR
Genes (Basel); 2022 Mar; 13(3):. PubMed ID: 35328025
[TBL] [Abstract][Full Text] [Related]
55. Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies.
Jung YW; Hysolli E; Kim KY; Tanaka Y; Park IH
Curr Opin Neurol; 2012 Apr; 25(2):125-30. PubMed ID: 22357218
[TBL] [Abstract][Full Text] [Related]
56. Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells.
Hu X; Mao C; Fan L; Luo H; Hu Z; Zhang S; Yang Z; Zheng H; Sun H; Fan Y; Yang J; Shi C; Xu Y
Stem Cells Int; 2020; 2020():1061470. PubMed ID: 32256606
[TBL] [Abstract][Full Text] [Related]
57. Induced pluripotent stem cell technology and direct conversion: new possibilities to study and treat Parkinson's disease.
Roessler R; Boddeke E; Copray S
Stem Cell Rev Rep; 2013 Aug; 9(4):505-13. PubMed ID: 22529017
[TBL] [Abstract][Full Text] [Related]
58. Modelling Parkinson's Disease: iPSCs towards Better Understanding of Human Pathology.
Avazzadeh S; Baena JM; Keighron C; Feller-Sanchez Y; Quinlan LR
Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33799491
[TBL] [Abstract][Full Text] [Related]
59. Mitochondrial CHCHD2: Disease-Associated Mutations, Physiological Functions, and Current Animal Models.
Kee TR; Espinoza Gonzalez P; Wehinger JL; Bukhari MZ; Ermekbaeva A; Sista A; Kotsiviras P; Liu T; Kang DE; Woo JA
Front Aging Neurosci; 2021; 13():660843. PubMed ID: 33967741
[TBL] [Abstract][Full Text] [Related]
60. Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease.
Bose A; Beal MF
Eur J Neurosci; 2019 Feb; 49(4):525-532. PubMed ID: 30408242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
